This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TCBP TC Biopharm (TCBP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisFDA EventsTrendsBuy This Stock About TC Biopharm Stock (NASDAQ:TCBP) Get TC Biopharm alerts:Sign Up Key Stats Today's Range$0.50▼$0.5050-Day Range$0.68▼$0.6852-Week Range$0.50▼$160.00VolumeN/AAverage Volume177,918 shsMarket Capitalization$205 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Read More Receive TCBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCBP Stock News HeadlinesWho is Bryan Kobel? Biotech CEO sues Uber after viral driver assault videoAugust 22, 2025 | msn.comTC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) PatientJune 11, 2025 | prnewswire.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.June 1 at 1:00 AM | Brownstone Research (Ad)TC BioPharm Holdings PLC (TCBPY)May 11, 2025 | investing.comTCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T CellsApril 9, 2025 | finance.yahoo.comTC BioPharm: TCBP Announces Transition from Nasdaq to OTC MarketsMarch 24, 2025 | finanznachrichten.deTC BioPharm to be delisted from Nasdaq, moves to OTC MarketsMarch 23, 2025 | uk.investing.comTC Biopharm announces transition to OTC Markets from NasdaqMarch 22, 2025 | markets.businessinsider.comSee More Headlines TCBP Stock Analysis - Frequently Asked Questions When did TC Biopharm's stock split? TC Biopharm shares reverse split on Monday, February 10th 2025.The 1-20 reverse split was announced on Wednesday, February 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did TC Biopharm IPO? TC Biopharm (TCBP) raised $17 million in an initial public offering on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton acted as the underwriter for the IPO. What other stocks do shareholders of TC Biopharm own? Based on aggregate information from My MarketBeat watchlists, some other companies that TC Biopharm investors own include Johnson & Johnson (JNJ), Procter & Gamble (PG), Taiwan Semiconductor Manufacturing (TSM), ExxonMobil (XOM), International Business Machines (IBM), NextEra Energy (NEE) and Union Pacific (UNP). Company Calendar Today6/01/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCBP CIK1872812 Webwww.tcbiopharm.com Phone44-14-1433-7557FaxN/AEmployees80Year Founded2013Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.67 Current Ratio1.12 Quick RatioN/A Sales & Book Value Annual Sales$4.76 million Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value$519.58 per share Price / Book0.00Miscellaneous Outstanding Shares410,000Free Float28,000Market Cap$205 thousand OptionableNot Optionable Beta0.01 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:TCBP) was last updated on 6/1/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share TC Biopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
